SCHEMBL17101378

SCHEMBL17101378

NNC(=O)C(CC(F)(F)F)C1(O)CCN(Cc2ccccc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 3/20 0.47
ALDH1A1 P00352 3/20 0.47
TSHR P16473 2/20 0.46
KMT2A Q03164 2/20 0.46
OPRL1 P41146 2/20 0.45
POLB P06746 3/20 0.44
USP2 O75604 1/20 0.43
CHRM2 P08172 1/20 0.43
CHRM3 P20309 1/20 0.43
DPP4 P27487 1/20 0.41
CCR3 P51677 1/20 0.41
CYP3A4 P08684 2/20 0.41
GAA P10253 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HIF1A Q16665 1/20 0.41
EPAS1 Q99814 1/20 0.41
LMNA P02545 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18075885 0.85 CYP2D6 (0.51) CYP2D6ALDH1A1TSHRKMT2AOPRL1
SCHEMBL17101274 0.81 CYP2D6 (0.51) CYP2D6ALDH1A1KMT2APOLBCHRM2
SCHEMBL23744794 0.72 OPRL1 (0.61) CYP2D6ALDH1A1TSHRKMT2AOPRL1
SCHEMBL2953304 0.72 CYP2D6 (0.55) CYP2D6ALDH1A1TSHROPRL1POLB
SCHEMBL11375974 0.71 KMT2A (0.60) CYP2D6ALDH1A1TSHRKMT2AOPRL1
SCHEMBL11374272 0.71 CYP2D6 (0.53) CYP2D6ALDH1A1TSHRKMT2AOPRL1
SCHEMBL17101429 0.71 CYP2D6 (0.51) CYP2D6ALDH1A1TSHRKMT2AOPRL1
SCHEMBL11836107 0.71 KMT2A (0.56) CYP2D6ALDH1A1TSHRKMT2AOPRL1
SCHEMBL11370652 0.71 CYP2D6 (0.60) CYP2D6ALDH1A1TSHRKMT2AOPRL1
SCHEMBL1313444 0.70 CYP2D6 (0.50) CYP2D6ALDH1A1TSHRKMT2AOPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12202843-B2 Muscarinic receptor agonists NXERA PHARMA UK LIMITED (GB) 2025-01-21 US disclosed
CN-110903306-B Muscarinic receptor agonists 赫普泰雅治疗有限公司 2022-09-23 CN disclosed
US-20220048928-A1 MUSCARINIC RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2022-02-17 US disclosed
US-20220048928-A1 MUSCARINIC RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2022-02-17 US disclosed
US-11034704-B2 Muscarinic receptor agonists NXERA PHARMA UK LIMITED (GB) 2021-06-15 US disclosed
US-11034704-B2 Muscarinic receptor agonists NXERA PHARMA UK LIMITED (GB) 2021-06-15 US disclosed
EP-3119396-B1 MUSCARINIC RECEPTOR AGONISTS HEPTARES THERAPEUTICS LTD (GB) 2021-05-05 EP disclosed
EP-3119396-B1 MUSCARINIC RECEPTOR AGONISTS HEPTARES THERAPEUTICS LTD (GB) 2021-05-05 EP disclosed
EP-3271358-B1 SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR HEPTARES THERAPEUTICS LTD (GB) 2020-11-18 EP disclosed
EP-3271358-B1 SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR HEPTARES THERAPEUTICS LTD (GB) 2020-11-18 EP disclosed
US-20180072727-A1 SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR NXERA PHARMA UK LIMITED (GB) 2018-03-15 US disclosed
EP-3271358-A1 SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR Heptares Therapeutics Limited (GB) 2018-01-24 EP disclosed
US-20170096437-A1 MUSCARINIC RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2017-04-06 US disclosed
US-20170096437-A1 MUSCARINIC RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2017-04-06 US disclosed
US-20170096437-A1 MUSCARINIC RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2017-04-06 US disclosed
EP-3119396-A1 MUSCARINIC RECEPTOR AGONISTS Heptares Therapeutics Limited (GB) 2017-01-25 EP disclosed
WO-2016147011-A1 SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR HEPTARES THERAPEUTICS LIMITED (GB) 2016-09-22 WO disclosed
WO-2016147011-A1 SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR HEPTARES THERAPEUTICS LIMITED (GB) 2016-09-22 WO disclosed
WO-2015140559-A1 MUSCARINIC RECEPTOR AGONISTS HEPTARES THERAPEUTICS LIMITED (GB) 2015-09-24 WO disclosed
WO-2015140559-A1 MUSCARINIC RECEPTOR AGONISTS HEPTARES THERAPEUTICS LIMITED (GB) 2015-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170096437-A1 MUSCARINIC RECEPTOR AGONISTS CHRM1, CHRM2, CHRM3 CYP2D6 717/4885ALDH1A1 3572/4885TSHR 90/4885
US-20220048928-A1 MUSCARINIC RECEPTOR AGONISTS CHRM1, CHRM2, CHRM3 CYP2D6 731/4885ALDH1A1 3554/4885TSHR 94/4885
US-12202843-B2 Muscarinic receptor agonists CHRM1, CHRM2, CHRM3 CYP2D6 731/4885ALDH1A1 3554/4885TSHR 94/4885
US-11034704-B2 Muscarinic receptor agonists CHRM1, CHRM2, CHRM3 CYP2D6 731/4885ALDH1A1 3554/4885TSHR 94/4885
US-20180072727-A1 SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR CHRM1, CHRM2, CHRM4 CYP2D6 582/4885ALDH1A1 1961/4885TSHR 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.